Gurbel, P A <br/><br/>
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.  [electronic resource] 

 -  Thrombosis and haemostasis  Sep 2014 
 - 589-97 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2567-689X 
<br/><br/><label>Standard No.: </label>10.1160/TH13-10-0891  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Clinical Protocols<br/>Clopidogrel<br/>Coronary Artery Disease--drug therapy<br/>Cytochrome P-450 CYP2C19--genetics<br/>Female<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Phenotype<br/>Piperazines--administration & dosage<br/>Platelet Aggregation--drug effects<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Polymorphism, Genetic<br/>Prasugrel Hydrochloride<br/>Thiophenes--administration & dosage<br/>Ticlopidine--administration & dosage<br/>Treatment Outcome